Iris Pharma merges with Clirophtha

Nice, France-Iris Pharma has completed its merger with Clirophtha and will operate under the name Iris Pharma. This is the first global drug-development services provider to be completely dedicated to ophthalmology clinical trials, according to the companies.

"The merger of Iris Pharma and Clirophtha is an opportunity to increase pharmaceutical and biotech companies' ability to develop the potential of their ophthalmologic drugs," said Pierre-Paul Elena, PhD, founder and chief executive officer of Iris Pharma.

"The cumulative expertise and experience from both Iris Pharma and Clirophtha guarantees that the new Iris Pharma company has excellent know-how and knowledge of each step of drug development, from pre-formulation and in vivo research to phase IV and medico-marketing surveys, as well as a global overview of the whole process," said Thierry Caillaud, business development director for the Pre-clinical Department at Iris Pharma.

"Our focus is on continuing to provide our customers with the best quality service and the best level of responsiveness. Our expertise and experience in ophthalmology guarantee our customers accurate consulting services at every stage of drug development," said Yann Quentric, business development director of Clirophtha. "We are more than a simple supplier-we act as a dedicated partner in helping our clients to take the right decision, at the right moment, to move forward efficiently and market their drugs faster."